Literature DB >> 11483314

Cerebellar synaptic protein expression in schizophrenia.

S L Eastwood1, D Cotter, P J Harrison.   

Abstract

A cortico-subcortico-cerebellar neural circuit has been postulated to be important in the pathophysiology of schizophrenia. This study investigated whether there are synaptic changes in the cerebellum to accompany its putative involvement in the disorder. We measured the expression of three synaptic proteins (synaptophysin, complexin I and complexin II) in the cerebellar cortex of 16 subjects with schizophrenia and 16 controls using in situ hybridisation histochemistry and immunoautoradiography. Complexin I and II are expressed predominantly by inhibitory and excitatory neurones respectively. In schizophrenia, synaptophysin mRNA was decreased, as was complexin II and its mRNA. Complexin I mRNA and protein levels were unaltered. Expression of the mRNAs in the rat cerebellum was unaffected by 2 weeks administration of antipsychotic drugs (haloperidol, chlorpromazine, risperidone, olanzapine or clozapine). We conclude that there is synaptic pathology in the cerebellum in schizophrenia. By disrupting neural circuits, the alterations may contribute to the cerebellar dysfunction thought to occur in the disorder.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483314     DOI: 10.1016/s0306-4522(01)00141-5

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  31 in total

Review 1.  The role of the cerebellum in schizophrenia.

Authors:  Nancy C Andreasen; Ronald Pierson
Journal:  Biol Psychiatry       Date:  2008-04-08       Impact factor: 13.382

2.  Cerebellar volume in schizophrenia and bipolar I disorder with and without psychotic features.

Authors:  C Laidi; M-A d'Albis; M Wessa; J Linke; M L Phillips; M Delavest; F Bellivier; A Versace; J Almeida; S Sarrazin; C Poupon; K Le Dudal; C Daban; N Hamdani; M Leboyer; J Houenou
Journal:  Acta Psychiatr Scand       Date:  2014-11-28       Impact factor: 6.392

3.  Peptide sharing between influenza A H1N1 hemagglutinin and human axon guidance proteins.

Authors:  Guglielmo Lucchese; Giovanni Capone; Darja Kanduc
Journal:  Schizophr Bull       Date:  2013-01-31       Impact factor: 9.306

4.  Safety and proof of principle study of cerebellar vermal theta burst stimulation in refractory schizophrenia.

Authors:  Asli Demirtas-Tatlidede; Catarina Freitas; Jennifer R Cromer; Laura Safar; Dost Ongur; William S Stone; Larry J Seidman; Jeremy D Schmahmann; Alvaro Pascual-Leone
Journal:  Schizophr Res       Date:  2010-12       Impact factor: 4.939

5.  RIM1alpha and interacting proteins involved in presynaptic plasticity mediate prepulse inhibition and additional behaviors linked to schizophrenia.

Authors:  Jacqueline Blundell; Pascal S Kaeser; Thomas C Südhof; Craig M Powell
Journal:  J Neurosci       Date:  2010-04-14       Impact factor: 6.167

Review 6.  Pre-clinical models of neurodevelopmental disorders: focus on the cerebellum.

Authors:  Alexey V Shevelkin; Chinezimuzo Ihenatu; Mikhail V Pletnikov
Journal:  Rev Neurosci       Date:  2014       Impact factor: 4.353

7.  Eye-blink conditioning deficits indicate temporal processing abnormalities in schizophrenia.

Authors:  Amanda R Bolbecker; Crystal S Mehta; Chad R Edwards; Joseph E Steinmetz; Brian F O'Donnell; William P Hetrick
Journal:  Schizophr Res       Date:  2009-04-05       Impact factor: 4.939

Review 8.  The neurobiology of D-amino acid oxidase and its involvement in schizophrenia.

Authors:  L Verrall; P W J Burnet; J F Betts; P J Harrison
Journal:  Mol Psychiatry       Date:  2009-09-29       Impact factor: 15.992

Review 9.  The role of the extracellular signal-regulated kinase pathway in cerebellar abnormalities in schizophrenia.

Authors:  Svetlana V Kyosseva
Journal:  Cerebellum       Date:  2004       Impact factor: 3.847

10.  Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia.

Authors:  Andrea Schmitt; Jiri Koschel; Mathias Zink; Manfred Bauer; Clemens Sommer; Josef Frank; Jens Treutlein; Thomas Schulze; Thomas Schneider-Axmann; Eleni Parlapani; Marcella Rietschel; Peter Falkai; Fritz A Henn
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-05-12       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.